Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 2/20 | 0.49 |
| ▸ | SIRT6 | Q8N6T7 | 5/20 | 0.47 |
| ▸ | HTR6 | P50406 | 7/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.43 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6080362 | 0.92 | POLB (0.45) | METLRRK2APPMAPTMAPK1 | |
| SCHEMBL6602148 | 0.92 | MET (0.49) | METSIRT6HTR6LRRK2MAPT | |
| SCHEMBL6081022 | 0.92 | ALDH1A1 (0.49) | APPMAPTMAPK1KMT2AALDH1A1 | |
| SCHEMBL6597740 | 0.83 | POLB (0.48) | METLRRK2MAPTMAPK1KMT2A | |
| SCHEMBL6597732 | 0.83 | POLB (0.48) | METLRRK2MAPTMAPK1KMT2A | |
| SCHEMBL6079319 | 0.83 | APP (0.45) | APPMAPTKMT2AALDH1A1 | |
| SCHEMBL6079326 | 0.83 | APP (0.45) | APPMAPTKMT2AALDH1A1 | |
| SCHEMBL6602382 | 0.82 | ALDH1A1 (0.44) | MAPTMAPK1KMT2AALDH1A1 | |
| SCHEMBL6080613 | 0.81 | CTSV (0.47) | APPMAPTKMT2AALDH1A1 | |
| SCHEMBL6080661 | 0.80 | APP (0.43) | APPMAPTKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NEURO3D (FR) | 2006-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NQO1, NQO2, RECQL | MET 4878/4885SIRT6 118/4885HTR6 2460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.